Pharmacologic, Pharmacokinetic, and Clinical Assessment of Illicitly Used γ-Hydroxybutyrate

J Clin Pharmacol. 2017 Jan;57(1):33-39. doi: 10.1002/jcph.767. Epub 2016 Jun 28.

Abstract

γ-Hydroxybutyrate (GHB) is a common drug of abuse and poses important health risks to users in the form of respiratory, cardiovascular, mental, or traumatic adverse events. GHB has non-dose-proportional effects and pharmacologic effects such as sedation and retrograde amnesia, which can incapacitate people targeted for assault. It has Krebs cycle metabolism, rapid clearance, relative hydrophilicity, and unique drug interactions. Promptly seeking medical attention during intentional or inadvertent overdose is critical to survival, as is prompt supportive care once medical personnel are alerted. People drugged before assault also need to promptly notify authorities because the period to detect the drug in the urine or blood is brief and the ultimate metabolites are carbon dioxide and water. After acute treatment has passed, withdrawal could be severe in chronic abusers that could harm the patient directly or drive them back into reuse.

Keywords: adverse events; pharmacology; withdrawal; γ-hydroxybutyrate.

Publication types

  • Review

MeSH terms

  • Anesthetics, Intravenous
  • Animals
  • Drug Overdose / blood
  • Drug Overdose / diagnosis
  • Humans
  • Illicit Drugs / adverse effects
  • Illicit Drugs / pharmacokinetics*
  • Rape / prevention & control
  • Sodium Oxybate / adverse effects
  • Sodium Oxybate / pharmacokinetics*
  • Substance Withdrawal Syndrome / blood
  • Substance Withdrawal Syndrome / diagnosis
  • Substance-Related Disorders / blood*
  • Substance-Related Disorders / diagnosis

Substances

  • Anesthetics, Intravenous
  • Illicit Drugs
  • Sodium Oxybate